Insider Purchases: Inside the Buy
Tag: Funanc1al Stocks to Watch
Bakkt Holdings CEO Buys Shares; Are Profits Baked In?
Bakkt (BKKT) is back on the radar. With a new CEO buying $1.47M of stock and losses shrinking fast, is this crypto play baked to perfection—or half-baked hype?
Can Olin Cock Its Stock? Insiders Say Yes (Lock, Load, and Maybe Profit)
Olin ($OLN) insiders are loading up on shares while institutions already own 94% of the float. Profits are weak, ammo is hot, and bleach is… bleach. Can this 132-year-old company cock its stock for a rebound?
iHeartMedia (IHRT): Turning the Volume Back Up?
Insiders are piling in, institutions are holding strong, and iHeartMedia is betting big on podcasts to fuel its turnaround. But with heavy debt and radio stagnation, is IHRT a hidden gem or just background noise?
Amrize Will Rise, Insiders Undoubtedly Think
Amrize insiders are loading up on stock like it’s on sale at Home Depot. With infrastructure and housing tailwinds, it’s tempting — but watch out for valuation cracks.
MaxCyte (MXCT) — Insiders Load Up While Cash Burns
MaxCyte insiders are shopping biotech shares like it’s Black Friday 🛒💉. With revenue slipping, cash burning, but institutions holding, is MXCT a comeback spark ⚡ or a treadmill burn-out 🔥?
Elite Buys Ely: Should You Buy Lilly’s Stock Too?
Eli Lilly insiders are opening their wallets after the company crushed Q2 2025 — revenue up 38%, EPS up 92%, and blockbuster drugs Zepbound and Mounjaro fueling a raised guidance. Institutions are all-in, the pipeline is buzzing, but the valuation is sky-high. Is LLY worth chasing at $639, or is patience the better prescription?
How Many Insider Buys Will It Take for The Bull in Enphase Energy to Re-energize?
After a brutal drop, Enphase Energy’s CEO is buying big. Institutions are all in. Margins hold strong. Could this be the spark the solar bull needs?
COO Goes Shopping: Is Molina Healthcare (MOH) a Healthy Buy or Just a Check-Up?
When the COO of Molina Healthcare spends $1.56M on stock, investors notice. With Wall Street titans on board and shares at major support, is this a healthy buy — or a risky patient?
Figma (FIG): Directors Buy In — Should You Collaborate?
🎨 Figma stock exploded out of the IPO gate, hitting highs nearly 5x insider purchase prices. With no profits, big Bitcoin bets, and stiff competition, is this design darling still worth the hype? Let’s sketch it out—icons, jokes, and all.
EPD: Enterprise Products Partners Is Boring—But It Pays to Be Boring
Enterprise Products Partners (EPD) might not make headlines, but it makes money. With insiders buying big, a solid 7% dividend, and decades of steady growth, this is one midstream stock that flows cash — not drama.